The company continues to expect to reach sustained operating profitability in the first half of 2025. Inari Medical exited the third quarter of 2024 with an improvement in overall revenues.
Inari Medical expects to showcase its PEERLESS data, which is one of the three randomized controlled trials (RCTs), in the second half of 2024. PEERLESS study is likely to evaluate patient ...